The resurgence of niacin: From nicotinic acid to niaspan/laropiprant

Israel Medical Association Journal

Volumn 13, Issue 6, 2011, Pages 367-373

  Markel, Arie ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

Author keywords

Extended release niacin (ERN); Hypercholesterolemia; Laropiprant; Niacin; Nicotinic acid

Indexed keywords

ACETYLSALICYLIC ACID; ACIFRAN; ACIPIMOX; ANTHRANILIC ACID DERIVATIVE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; CLOFIBRATE; COLESTIPOL; EZETIMIBE; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HM74 RECEPTOR; HM74A RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0354; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TREDAPTIVE MSD; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY OBSTRUCTION; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTENDED RELEASE FORMULATION; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTENSION; LIPOLYSIS; LIPOPROTEIN SYNTHESIS; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MYOPATHY; OPTIMAL DRUG DOSE; PROSTAGLANDIN RELEASE; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TOXIC HEPATITIS; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VASODILATATION;

EID: 79959961845     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008; 153: S68-S75.
2. Gilutz H, Novack L, Shvartzman P, et al. Computerized Community Cholesterol Control (4C): meeting the challenge of secondary prevention. IMAJ Isr Med Assoc J 2009; 11: 23-29.
3. Whayne TF Jr, Zielke JC. Triglyceride level: a predictive risk factor for atherosclerosis? Arch Intern Med 2001; 161: 295-296.
4. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-1036.
5. Hussein AA, Nicholls SJ. Critical appraisal of laropiprant and extendedrelease niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Ther Clin Risk Manag 2010; 6: 183-190.
6. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
7. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-341.
8. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357 (21): 2109-2122.
9. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955; 54: 558-559.
10. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15: 659-665.
11. th anniversary review. J Intern Med 2005; 258: 94-114.
12. Kamanna VS, Ganji SH, Kashyap ML. Niacin: an old drug rejuvenated. Curr Atheroscler Rep 2009; 11: 45-51.
13. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21: 1783-1789.
14. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-381.
15. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
16. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-3240.
17. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
18. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88: 20-28.
19. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
20. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158: 429-441.
21. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008; 48: 79-106.
22. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202: 68-75.
23. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extendedrelease niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 74-81.
24. Papaliodis D, Boucher W, Kemperaj D, et al. Niacin-induced 'flush' involves release of PGD2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther 2008; 327: 665-672.
25. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007; 100: S53-S61.
26. Martres P. HM74a agonists: will they be the new generation of nicotinic acid? [Review]. Curr Top Med Chem 2009; 9: 428-435.